Newsletter – March 2nd 2023

NEWSLETTER: Nasally Delivered Dry Powder Dosage Forms: Particle Size Analysis Introduction to Nasal Delivery The delivery of APIs via nasal inhalation is of growing interest to companies looking to exploit the benefits of this delivery route. Delivery targets are typically broken down into three categories Local delivery to the nasal membranes (e.g. for vaccines, antivirals, … Read more

Newsletter – January 31st 2023

NEWSLETTER: What’s New In 2023: ExcitingPlans For Upperton Pharma Solutions! The New Year is always a time for looking ahead and 2023 will no doubt turn out to be a pivotal year in the Upperton Pharma Solutions growth story. In this Newsletter we will be previewing some of the exciting new plans that we have … Read more

Newsletter – December 21st 2022

NEWSLETTER: Seasons Greetings To All Of Our Customers Traditionally at this time of year we like to offer Season’s Greetings to all our customers and friends and whilst doing so, look back over the years at some of the highlights in what has been an exceptionally busy (and successful) year for Upperton Pharma Solutions! Here … Read more

Newsletter – November 16th 2022

Upperton Launches ASAPprime® Shelf-Life Stability Testing Upperton has made a significant investment in ASAPprime® software and hardware to enable the company to offer its clients state of the art stability testing. This exciting new platform can be used to generate robust, accelerated chemical stability data and is now being applied at all stages of the … Read more

Newsletter – September 15th 2022

In Vitro Testing of Dry Powder Nasal Delivery Devices Successful nasal drug delivery of dry powder formulations requires a delivered dose that can penetrate beyond the nasal entrance region and deposit in the peripheral nasal cavity, whilst avoiding deeper penetration to the airways of the lungs. This delivery, or deposition pattern, is determined by the … Read more

Newsletter – August 16th 2022

Latest News from Upperton Pharma Solutions Successful MHRA Inspection Upperton is delighted to announce that during the last week of July 2022 the UK MHRA conducted a routine, three day inspection of the GMP facility and Quality Control testing laboratories following which, no Critical or Major observations were raised. Speaking after the inspection, CEO Nikki … Read more

Newsletter – June 23rd 2022

Characterising the physical properties of spray dried powders The benefits of powder characterisation When developing products containing spray dried powders it is vital that the physical properties of the powders produced are determined. The physical properties of spray dried powders provides important information that can assist during the pre-formulation screening and early process development phases … Read more

Newsletter – February 24th 2022

Growing Interest in Nasal Delivery Recent trends have seen growing interest in exploiting nasal delivery as a means of delivering a wide range of drugs including small molecules and larger biologics for a wide range of indications. The nasal cavity is already a well-established delivery route capable of achieving rapid and high level of drug … Read more

Newsletter – January 27th 2022

Upperton Adds New Nasal and Oral Delivery Technologies Upperton is pleased to announce that it has bolstered its nasal and oral delivery capabilities with the addition of a number of new analytical and formulation technologies. Nasal Delivery News – Upperton enhances its analytical capabilities by acquiring next generation nasal particle impaction technology Upperton has acquired the … Read more

Newsletter – January 13th 2022

What’s New In 2022: Exciting Plans For Upperton Pharma Solutions! Happy New Year to all of our customers and our friends across the industry! There is no doubt that 2021 was a challenging year for everyone in one way or another, but its fair to say that it was also a year of progress and … Read more